1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(methylaminomethoxymethyl)oxolan-2-yl]pyrimidine-2,4-dione

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(methylaminomethoxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
• 化学式: C₁₁H₁₇N₃O₆
• 分子量: 287.27
• InChiKey: SIMALCICGSCVGK-PEBGCTIMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  120
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA
  申请人：Moderna Therapeutics, Inc.

  公开号：EP2964234A1

  公开（公告）日：2016-01-13
• [EN] HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA<br/>[FR] RÉGIONS NON TRADUITES HÉTÉROLOGUES POUR ARNM
  申请人：MODERNA THERAPEUTICS INC

  公开号：WO2014164253A1

  公开（公告）日：2014-10-09

  The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture. Described herein are compositions and methods for the manufacture and optimization of modified mRNA molecules via alteration of the terminal architecture of the molecules. Specifically disclosed are methods for increasing or altering protein production or localization by altering the 5 'UTR of modified mRNAs. In one aspect, provided is a synthetic isolated RNA comprising a first region of linked nucleosides encoding a polypeptide of interest, a first flanking region located at the 5' terminus of the first region, a second flanking region located at the 3' terminus of the first region and a 3' tailing region of linked nucleosides. Any of the first region, first flanking region, second flanking region or a 3' tailing region may comprise at least one modified nucleoside.